Praxis Precision Medicines (PRAX) Q2 2026 earnings summary

Executive summary

• Transitioned from a development-stage to a commercial-stage organization, with NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEE) in late-stage FDA review, no major safety or efficacy concerns, and approvals expected within six months.

• Commercial infrastructure, including leadership, field force, and distribution, is in place for both launches, with inventory being built and patient support programs established.

• Received third Breakthrough Therapy Designation for elsunersen after positive EMBRAVE Part A trial results for SCN2A DEE.

• Ongoing clinical programs for vormatrigine and multiple preclinical ASO candidates, with POWER2 and POWER3 studies planned to initiate in Q4 2026.

• Terminated UCB collaboration, regaining full rights to KCNT1 program.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $1.4 billion as of June 30, 2026, up from $926 million at year-end 2025, providing runway into 2028.

• Q2 2026 operating expenses were $96.9 million, up from $76 million in Q2 2025, driven by increased R&D ($69.4 million) and G&A ($27.5 million) spending.

• Net loss for Q2 2026 was $83.7 million, compared to $71.1 million in Q2 2025.

• Other income rose to $13.2 million in Q2 2026, primarily from interest income.

• No product revenue generated; gross margin not applicable.

Outlook and guidance

• Both ulixacaltamide and relutrigine launches are expected in early 2027, with commercial teams fully hired and launch readiness ahead of PDUFA dates.

• Cash position expected to fund operations into 2028, supporting ongoing R&D, clinical trials, and commercialization activities.

• Topline results for relutrigine's EMERALD study expected in Q4 2026; EMBRAVE3 trial for elsunersen progressing with results anticipated in 2027.

• G&A expenses expected to increase in the second half of 2026 to support launches, including expanded commercial field teams and awareness campaigns.

• Vormatrigine program to be revamped with new study designs (POWER2 and POWER3) based on learnings from POWER1, with studies restarting in Q4 2026.